Clinical Trial Update: Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating cytarabine and mitoxantrone with venetoclax for relapsed or refractory acute myeloid leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Mitoxantrone (mitoxantrone)
• Venetoclax (venetoclax)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Relapsed Adult AML, Refractory AML | Phase 1, Phase 2 | Status: UNKNOWN